Podcasts

Insights from scientific pioneers, founders and healthcare leaders shaping the future of medicine

Subscribe and listen

S02 • E07

ASCO: The Biggest Event in Oncology

Full details

You must accept preferences cookies and refresh your browser to view this content.

Alternatively, if cookies are being blocked by the browser, or you wish to view the content at its source, you can do so by visiting the link below: https://player.rss.com/rtwinvestments/2846827

This episode of The RTW Podcast features Senior Research Analyst Chris Liu, speaking with RTW Partner and Chief Business Officer, Stephanie Sirota.

Previous episodes

Women’s Health: An Investing Whitespace

S02 • E06
Stephanie Sirota and Dr. Stephanie Lam discuss perimenopause and menopause, the recent FDA changes to hormone replacement therapy, and a holistic view of women's health.
Listen now

Gene Editing: From CRISPR to Curative Medicine

S02 • E05
Stephanie and John discuss gene editing and gene therapy, base and prime editing, Beam's work in treating Alpha-1 antitrypsin deficiency (A1AT), and John's journey into the biotech industry.
Listen now

Biotech’s New Era: Innovation and Commercialization

S02 • E04
This episode of The RTW Podcast features Chief Business Officer Stephanie Sirota speaking with Rod Wong, Managing Partner and Chief Investment Officer of RTW Investments.
Listen now

The Split Vote: UroGen and the FDA

S02 • E03
This episode of The RTW Podcast features Chief Business Officer Stephanie Sirota speaking with UroGen Pharma President and CEO Liz Barrett.
Listen now

14 Months to Treatment: Breaking Records in Rare Disease Therapy

S02 • E02
This episode of The RTW Podcast features Chief Business Officer Stephanie Sirota speaking with Michelle Krueger, Managing Director at Alvarez and Marsal and Co-Founder of Elly's Team.
Listen now

Losing Sleep and Lives: Matthew Walker on the Global Sleep Epidemic

S02 • E01
This episode of The RTW Podcast features Chief Business Officer Stephanie Sirota speaking with sleep scientist and author Matthew Walker.
Listen now
Show more

Featured on...

Vanguards of Health Care: RTW on Biotech's Bull Case

May 07, 2026
Listen now

Biotech Investing at Scale: Turning Deep Uncertainty into Transformative Health Outcomes

April 29, 2026
Listen now

Insightful Investor: Rod Wong: Biotech Innovation, Real Outcomes

April 07, 2026
Listen now

Biotech investors’ plea to Trump, and a busy M&A week

April 02, 2026
Listen now

The Weight of the Moment: How GLP-1s are Rewiring Biotech Investing, Expert Analysis

April 01, 2026
Listen now

Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides

January 29, 2026
Listen now

Investor Insights Podcast #55 - Roderick Wong MD, Founder and CIO at RTW Investments

June 13, 2025
Listen now

Stephanie Sirota, CBO & Partner at RTW Investments, on Biotech Investing, Policy & Bold Bet Building

May 27, 2025
Listen now

RTW: Investing Across Healthcare

September 28, 2024
Listen now

Empty Rooms: Innovation in Biotech at RTW, Interview with Rod Wong

April 24, 2024
Listen now

Appetite for Change: The Obesity Epidemic Meets Biotech

March 19, 2024
Listen now

Rod Wong Joins Interactive Investors' On The Money Podcast

November 21, 2023
Listen now

Stephanie Sirota discusses the biotech innovation market

October 11, 2022
Listen now

Rod Wong featured guest on the BIOS Ventures podcast with Alix Ventures' Chris Ghadban

September 12, 2022
Listen now

This website is not intended to offer or to promote the offer or sale of the shares (the “Shares”) of RTW Biotech Opportunities Ltd (the “Company”) in the United States or to any “U.S. persons” as defined in Regulation S (“US persons”) under the US Securities Act of 1933, as amended (the “Securities Act”). The materials contained herein are not for release, publication or distribution, directly or indirectly, in whole or in part, to any persons to whom or into or within any jurisdiction where to do so would constitute a violation of applicable law or regulation.

The information contained herein and on the pages that follow does not constitute or form a part of any offer to sell or issue, or the solicitation of any offer to purchase, subscribe for or otherwise acquire, any securities in the United States or in any jurisdiction in which, or to any person to whom, such an offer or solicitation would be unlawful.

The Company has not been and will not be registered under the US Investment Company Act of 1940, as amended (the “Investment Company Act”), and as such holders of the Shares are not and will not be entitled to the benefits of the Investment Company Act. The Shares have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction of the United States, and may not be offered, sold, resold, pledged, delivered, assigned or otherwise transferred, directly or indirectly, into or within the United States or to, or for the account or benefit of, any US Persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not result in the Company being required to register under the Investment Company Act. There has been and will be no public offer of the Shares in the United States. The offer and sale of the Shares have not been and will not be registered under the applicable securities laws of Australia, Canada, Japan or South Africa. Potential users of the information contained herein and on the pages that follow are requested to inform themselves about and to observe all applicable restrictions.

The information contained herein and on the pages that follow may contain forward-looking statements. Any statement other than a statement of historical fact is a forward-looking statement. Actual results may differ materially from those expressed or implied by any forward-looking statement. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. You should not place undue reliance on any forward-looking statement, which speaks only as of the date of its issuance. The Company may change these terms and conditions from time to time and any such changes will be posted on this website. Your access to this website is governed by the version of these terms and conditions then in force.

By clicking “Agree” below, you represent, warrant, undertake and agree that (1) you have read, understood and agree to be bound by the terms and conditions and other information set out herein, (2) you are permitted under applicable laws and regulations to receive the information contained herein and on the pages that follow, (3) you are either (a) located outside the United States and are not a US Person or (b) an existing shareholder of the Company who is a “qualified purchaser” as defined under the Investment Company Act and (4) you will not further transmit or send any information contained in this website to any other persons in the United States, to US Persons, or to any publications with a general circulation in the United States. If you cannot so represent, warrant, undertake and agree, you must click the button labelled “Decline” or otherwise exit this website.

You must accept preferences cookies and refresh your browser to view this video.

Alternatively, if cookies are being blocked by the browser, or you wish to view the video at its source, you can do so by visiting the link below: